AVN316

AVN316 is a potent and highly selective small molecule antagonist of the 5-hydroxytryptamine receptor 6 (5-HT6), developed by Avineuro. The 5-HT6 receptor is primarily localized in brain regions associated with cognitive function, such as the hippocampus and cortex. By antagonizing this receptor, AVN316 facilitates the release of neurotransmitters like acetylcholine and glutamate, which are often depleted in neurodegenerative and neuropsychiatric conditions. The drug has been investigated in clinical trials for its potential to improve cognitive symptoms in patients with Alzheimer's disease and schizophrenia. Preclinical data suggested a favorable safety profile and high brain permeability, distinguishing it from earlier 5-HT6 antagonists that faced challenges with selectivity or metabolic stability.